A Multicenter, Partially-blinded, Randomized, 24-week, Parallel-group, Non-inferiority, Open-label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate; Tiotropium bromide
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ARGON
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.
- 02 Feb 2018 Planned primary completion date changed from 29 Mar 2019 to 21 Jun 2019.
- 02 Feb 2018 Planned initiation date changed from 15 Jan 2018 to 5 Feb 2018.